Sensorion To Present Data From Phase Ib Clinical Trial Of SENS-111 At AAO-HNSF Annual Meeting

Data Support Further Development of Innovative Treatment for Acute Peripheral Vertigo

MONTPELLIER, France--(BUSINESS WIRE)--Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) , a biotech company specializing in the treatment of inner ear diseases, announced today that safety and pharmacokinetic data from its Phase 1b clinical trial of SENS-111 has been accepted for poster presentation at the American Academy of Otolaryngology-Head and Neck Surgery Foundation’s 2016 Annual Meeting & OTO EXPO to take place in San Diego, CA September 18-21, 2016.

Poster title: SENS-111, H4 Antagonist for Treatment of Peripheral Vertigo, Is Safe

Poster number and presentation location will be communicated later by the organizers of the scientific conference.

Pierre Attali, Sensorion’s Chief Medical Officer, says: “We are pleased to have clinical data of SENS-111 accepted for presentation at the AAO-HNSF annual meeting. We believe this demonstrates the need recognized by researchers and physicians in the field of otology for an oral treatment for acute vertigo that is safe and effective. With SENS-111, as well as with our pipeline of first-in-class small molecule oral products, we strive to provide patients with an improved and convenient treatment option for inner ear diseases. We look forward to presenting this poster at the upcoming conference and highlighting the potential of our products in this large global market.”

About SENS-111

SENS-111 is the first representative of the histamine type 4 receptor antagonist class tested in inner-ear pathologies. This drug candidate displays a neuromodulation effect of the neurosensorial inner ear cell function and is being developed for the symptomatic treatment of bouts of vertigo or tinnitus. SENS-111 is a small molecule that can be taken orally or via a standard injection, and has been successfully assessed in humans in phase 1b.

Name: SENSORION
ISIN code: FR0012596468
Ticker: ALSEN